IMVT
- Immunovant, Inc.
()
Overview
Company Summary
Immunovant, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for chronic autoimmune and inflammatory diseases. The company aims to address unmet medical needs by targeting the underlying cause of these diseases rather than just managing the symptoms.
Immunovant primarily focuses on developing novel biologic therapies that utilize a mechanism called neonatal Fc receptor (FcRn) to modulate the function of disease-causing pathogenic autoantibodies. FcRn is a protein that regulates antibody homeostasis in the body and plays a key role in the recycling and clearance of immunoglobulin G (IgG) antibodies.
The company's lead investigational product, IMVT-1401, is an anti-FcRn monoclonal antibody designed to reduce IgG antibody levels and thereby mitigate the symptoms and progression of autoimmune diseases. IMVT-1401 is being evaluated in clinical trials for several indications, including myasthenia gravis, a rare neuromuscular disorder, and warm autoimmune hemolytic anemia, a condition characterized by the destruction of red blood cells due to autoantibodies.
Immunovant's innovative approach focuses on inhibiting the FcRn pathway to reduce antibody-mediated diseases' impact on patients' lives. By specifically targeting the underlying cause, rather than simply managing symptoms, Immunovant aims to provide more effective and durable treatment options for patients suffering from chronic autoimmune and inflammatory diseases.